Larisa Reyderman

Eisai (United States) — United States

Medicine · Health Sciences

28h-index8.0kcitations142works5.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(35), Cancer Treatment and Pharmacology(25), Computational Drug Discovery Methods(17), Colorectal Cancer Treatments and Studies(14), Cholinesterase and Neurodegenerative Diseases(13)

Publications142 total

Tau biology, biomarkers, and therapeutics
Alzheimer s & Dementia Translational Research & Clinical Interventions·2025Open Access
An Anti-tau Therapeutic Antibody Etalanetug (E2814)
Alzheimer Disease & Associated Disorders·2025· 2 citedOpen Access
The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer’s Disease (P1-3.003)
Neurology·2025· 2 cited
Lecanemab Maintenance Dosing in Early Alzheimer’s Disease: Support for Continued Dosing from Clinical, Pharmacology, and Modeling Data (S23.007)
Neurology·2025· 2 cited
Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
Alzheimer s & Dementia Translational Research & Clinical Interventions·2025· 4 citedOpen Access
How Does the Latest Clinical Pharmacology Data & Modeling Support Continued Lecanemab Dosing?
Alzheimer s & Dementia·2024· 1 citedOpen Access
Lecanemab Slows Tau PET Accumulation
Alzheimer s & Dementia·2024· 6 citedOpen Access
"Paradoxical” Cerebral Volume Changes in Anti‐Amyloid Immunotherapy Trials
Alzheimer s & Dementia·2024· 1 citedOpen Access
Long‐Term Effects of Lecanemab on Biomarkers of Neurodegeneration in Plasma
Alzheimer s & Dementia·2024· 2 citedOpen Access
Amyloid Plaque Reduction as a Surrogate Marker of Efficacy: Assessment of Amyloid PET and Change in CDR‐SB Utilizing Semi‐Mechanistic Model
Alzheimer s & Dementia·2024Open Access
Prediction of regional brain tau levels in early Alzheimer’s disease using plasma pTau217
Alzheimer s & Dementia·2024Open Access
Lecanemab Slows Amyloid‐Induced Tau Pathology as Supported by CSF MTBR‐tau243 in Clarity AD
Alzheimer s & Dementia·2024· 4 citedOpen Access
Model‐Based Assessment of Lecanemab Maintenance Dosing Regimen Shows Continued Suppression of Amyloid Plaque, Disease Progression
Alzheimer s & Dementia·2024· 2 citedOpen Access
Neuro‐Dynamic Quantitative Systems Pharmacology (Qsp) Model Supports Continued Lecanemab Treatment With Maintenance Dosing For Alzheimer’s Disease
Alzheimer s & Dementia·2024Open Access
Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid‐positive early Alzheimer's disease
Alzheimer s & Dementia·2024· 12 citedOpen Access
Population pharmacokinetics and exposure–response analyses of safety (<scp>ARIA</scp>‐E and isolated <scp>ARIA</scp>‐H) of lecanemab in subjects with early Alzheimer's disease
CPT Pharmacometrics & Systems Pharmacology·2024· 11 citedOpen Access
Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease
Alzheimer s & Dementia·2024· 36 citedOpen Access
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force
The Journal of Prevention of Alzheimer s Disease·2024· 16 citedOpen Access
Exposure-Response Modeling to Describe Change in Brain Amyloid Following Lecanemab Administration in Patients with Early Alzheimer’s Disease (P9-9.011)
Neurology·2024
A Neuro-Dynamic Quantitative Systems Pharmacology (QSP) Model to Describe Pathophysiology of Alzheimer’s Disease and Inform Drug Development
2024Open Access
page 1 of 8Next →

Frequent Co-authors

Paul Statkevich(12), Teddy Kosoglou(9), Chad J. Swanson(7), Shobha Dhadda(7), Lynn D. Kramer(7), David L. Cutler(7), Michael C. Irizarry(5), Akihiko Koyama(5), Stephen E. Maxwell(5), J. Wanders(5), G. Edwards(5), Jan H.M. Schellens(5), Salomon Stavchansky(5), Marja Mergui‐Roelvink(4), Jos H. Beijnen(4), Randall J. Bateman(3), Michio Kanekiyo(3), Lars Lannfelt(3), Jeffrey L. Cummings(3), L.J.C. Pember(3)